Janet Downie is the CEO of RoslinCT. Janet has over 20 years’ experience in biologics manufacturing and testing and was previously the COO for Roslin Cells Ltd and part of the original team that established the business. She then went on to set up the contract manufacturing division prior to the establishment of RoslinCT.
Janet has held various senior roles in operations and quality within Inveresk Research, PPL Therapeutics and Charles River Laboratories. She has always had a passion for business growth through delivering a quality service and a focus on patient safety. Janet holds a BSc (Hons) in Biological Sciences and is a member of UK Task force for ATMP Manufacturing and the BIA Cell Therapy and Manufacturing Committees.
Janet has a love for animals and has a house full of dogs and cats. She would have more if she could. She also enjoys spending time in the countryside and has recently developed a passion for fishing.
David is responsible for all Finance related areas within the business and joined RoslinCT in 2017 to support the company’s strategic growth plans.
David has over 30 years Financial and Commercial experience in a number of businesses within the Service Industries and was part of the team who grew and subsequently sold a global leading contract manufacturing and development organisation focused on liquid and semi-solid capsule products to a major US Pharmaceutical company.
David enjoys Golf and World Travel and spending time with his grandchildren.
Sue is Head of Commercial and joined RoslinCT in 2015. She has extensive experience in the life sciences industry and a particular interest in bringing new therapeutic products to the market. Previously, she held various business development positions, most recently for the University of Edinburgh, working with academics and clinicians within NHS Lothian to commercialise and manage IP arising from the College of Medicine. Previous project management and commercial expertise was gained within various CMO's, each providing GMP services to clients, including SNBTS, Angel Biotechnology Ltd, and Catalent Pharma Solutions in the USA.
Sue’s early career started at PPL Therapeutics as a Biochemist, where she developed characterisation and novel purification strategies for genetically modified proteins expressed in the milk of transgenic animals.
Sue enjoys horse riding, hill walking and looks forward to skiing trips in the winter months, preferably somewhere warmer than in Scotland!
Dr Laura Kennedy
Laura has worked for RoslinCT since 2010. She has responsibility for ensuring regulatory compliance for all Quality Control activities. These activities include ensuring the continuing performance of the cleanroom facility at the Scottish Centre for Regenerative Medicine and the design, scheduling and implementation of QC testing regimes within a GMP environment to support manufacturing projects.
She previously worked within the Translational Medicine field as a Post-Doctoral Scientist in the Genomics team as part of the Translational Medicine Research Collaboration. Her research career prior to this was focused on Neurodegenerative diseases with Post-doctoral work in the Alzheimer’s Disease field and a Ph.D gained with a studentship awarded from the Huntington’s Disease Association.
She is passionate about her work on the manufacture of cellular therapies, which have the potential to successfully treat and provide hope to many people currently suffering from debilitating disorders.
Kim specialises in the manufacture of cell based medicinal products and therapies. She joined RoslinCT in 2012 and has since fulfilled managerial roles in both Quality Assurance and Quality Control Department’s before moving into the Manufacturing Department.
During her career she has developed considerable experience in the development, translation and testing of cell based medicinal products and therapies. Kim moved into contract testing and manufacture with Charles River in 2001, and held a number of quality and regulatory roles within this company for over 11 years, supporting the conduct of GLP testing and Phase 1 clinical trials.
Personal experience of the impact of degenerative illness, means Kim has an ardent interest in new cellular therapies and the benefits these could have on patients.
Kim holds a first class Bachelor of Science degree in Applied Microbiology.
Kim enjoys travelling and spending time with her family, and is a keen, if not particularly accomplished, runner.
Dr Lindsay Fraser
Lindsay joined the team in 2012 to establish the induced pluripotent stem cell (iPSC) core facility. She now has responsibility for leading the cell therapy research and development projects, and in the translation of research protocols to regulatory compliant GMP manufacturing processes. The development team design and optimise complementary cell characterisation assays to monitor cell health during processing.
Lindsay finds her role is constantly evolving, in response to novel advances in regenerative medicine. She has a passion for the development and implementation of new technology and in helping cell therapy products reach the clinic.
She has experience in regenerative medicine, GMP processing and cellular therapy application, working across clinical, academic and commercial sectors including the Scottish National Blood Transfusion Service, Edinburgh University (PhD), Miltenyi Biotec and Biobest Laboratories.
Lindsay loves the great outdoors, festivals and time out with friends and family.